Use of an Ang-(1-7) Receptor Agonist in Acute Lung Injury

With age-adjusted incidences of 86 per 100.000 person-years and overall mortality rates of about 43%, acute lung injury (ALI) and its most severe form, the acute respiratory distress syndrome (ARDS), remains a major cause of death in intensive care. So far, the only evident improvement for the survival of ARDS patients has been achieved by the implementation of minimal invasive ventilation strategies with low tidal volumes as compared to the previously used high tidal volumes. Ang-(1-7) or related agonists may represent a new and promising strategy for the treatment of ALI/ARDS. The present invention provides means and methods for a pharmacological intervention in the patho-physiologic events underlying ALI/ARDS.

Further Information: PDF

ipal GmbH
Phone: +49 (0)30/2125-4820

Contact
Ursula Haufe

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Superradiant atoms could push the boundaries of how precisely time can be measured

Superradiant atoms can help us measure time more precisely than ever. In a new study, researchers from the University of Copenhagen present a new method for measuring the time interval,…

Ion thermoelectric conversion devices for near room temperature

The electrode sheet of the thermoelectric device consists of ionic hydrogel, which is sandwiched between the electrodes to form, and the Prussian blue on the electrode undergoes a redox reaction…

Zap Energy achieves 37-million-degree temperatures in a compact device

New publication reports record electron temperatures for a small-scale, sheared-flow-stabilized Z-pinch fusion device. In the nine decades since humans first produced fusion reactions, only a few fusion technologies have demonstrated…

Partners & Sponsors